Stock comparison
Bruker
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BRKR
Bruker
Market cap
$6.96B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BRKR | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 33F | 77B | LMAT |
| Benjamin Graham | 44D | 89A | LMAT |
| Philip Fisher | 38D | 81C | LMAT |
| Peter Lynch | 30F | 67B | LMAT |
| Joel Greenblatt | 42D | 56D | LMAT |
| Charlie Munger | 40D | 68D | LMAT |
| Terry Smith | 38D | 69D | LMAT |
Side-by-side metrics
| Metric | BRKR | LMAT |
|---|---|---|
| Market cap | $6.96B | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 34.2x | 36.6x |
| ROIC (TTM) | -2.92% | 9.43% |
| Gross margin | 45.56% | 72.39% |
| Net margin | -0.34% | 24.35% |
| Revenue CAGR 5y | 9.19% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.7x | 0.5x |
| Dividend yield | 0.47% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BRKR leads on
- P/E (TTM)-vs 37.1x+107%
- Market cap$6.96Bvs $2.23B+68%
- EV/EBIT34.2xvs 36.6x+7%
LMAT leads on
- ROIC (TTM)9.43%vs -2.92%+131%
- Net margin24.35%vs -0.34%+101%
- Dividend yield0.84%vs 0.47%+44%
- Gross margin72.39%vs 45.56%+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.